In a recent pooled analysis on 43 patients with metastatic ncc-RCC or with clear cell cancer with >20% sarcomatoid or rhabdoid differentiation treated with a PD1 or PD-L1 targeting agent (either as monotherapy or in association), the overall response rate was 31% in treatment-naive patients [167]. The gene discussed is RPL17; the disease is renal cell adenocarcinoma.